ReviewClinical and vaccine immunology : CVI2014
Antibodies for treatment of Clostridium difficile infection.
Review in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- PhosphoLipidome Alteration Induced byCells · 2024Article
- Biofilm Formation ofMicroorganisms · 2023Review
- Review
- Review
- Application of recombinant antibodies for treatment ofFrontiers in immunology · 2022Review
- Review
- Humoral response toJGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Recent advances in the treatment ofInfection and drug resistance · 2019Article
- Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrentBiologics : targets & therapy · 2018Review
- Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.Journal of molecular biology · 2017Article
- Bezlotoxumab.Hospital pharmacy · 2017Article
- A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.BMC infectious diseases · 2016Article
- Breakthroughs in the treatment and prevention of Clostridium difficile infection.Nature reviews. Gastroenterology & hepatology · 2016Review
- An update on antibody-based immunotherapies for Clostridium difficile infection.Clinical and experimental gastroenterology · 2016Review
- Exposure of neutralizing epitopes in the carboxyl-terminal domain of TcdB is altered by a proximal hypervariable region.The Journal of biological chemistry · 2015Article
- Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.PloS one · 2015Article
- A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors.BMC systems biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies for the treatment of Clostridium difficile infection (CDI) have been demonstrated to be effective in the research and clinical environments. Early uncertainties about molecular and treatment modalities now appear to have converged upon the systemic dosing of mixtures of human IgG1. Although multiple examples of high-potency monoclonal antibodies (MAbs) exist, significant difficulties were initially encountered in their discovery. This minireview describes historical and contemporary MAbs and highlights differences between the most potent MAbs, which may offer insight into the pathogenesis and treatment of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.